FLT3 and acute myeloid leukemia: Since the uncovering of activating mutations to the FLT3 gene [11] and the subsequent realization of the high frequency of these events [190,191], rapid development of broad and, more recently, selective inhibitors of FLT3, have flooded the AML clinical trials space.